AlphAIAlphAI — Financial news for AI agents
investing.comNOV 32 min read$RVTY

Why is Revvity stock surging today?

Revvity (RVTY) stock rose 8.8% in pre-market trading after its Q3 2026 earnings beat estimates, with adjusted EPS of $1.37 and revenue of $729M. The company raised its full-year guidance, citing strong segment growth and margin expansion. CEO Prahlad Singh highlighted broad-based growth. The move was driven by company-specific news, not broader market trends. TD Cowen had previously raised its price target to $175.

Original reporting
investing.com
Published Nov 3, 2026, 12:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 1:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$RVTY
Bullish
high confidence
Mentioned
$RVTY
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$RVTYBullishHigh
01

Why it matters

The earnings beat and guidance raise provide a fresh catalyst, likely extending the stock's rally toward its 52‑week high.

02

Market read

Strong earnings and guidance lift Revvity sharply, creating a short‑term trading opportunity.

03

What to watch

Potential supply‑chain constraints or slower adoption of new products could temper growth.

Relevance 8/10Novelty 9/10Timing: pre‑market today

Background

Revvity (RVTY) is a life‑sciences instrumentation company that has been recovering throughout 2026.

Company-level read

Ticker impact

$RVTYBullishHigh confidence
Context

Revvity posted Q3 2026 earnings that beat estimates and raised full-year guidance, driving an 8.8% pre‑market surge.

Expected impact

upward pressure as investors price in the earnings beat and higher guidance

Evidence & confidence

Both EPS and revenue exceeded consensus, and guidance was lifted above prior expectations, providing a clear catalyst for further buying.

Market effects

Sector

Life‑sciences segment shows strong growth, may lift peers in the sector.

Regional

Positive for US biotech and life‑sciences stocks.

Global

Limited; impact confined to Revvity and related US biotech equities.

Counterpoint

What could challenge this read

If the guidance raise is overly optimistic, the stock could face a pull‑back after the initial rally.

Key entities

  • Company
    Revvyty Inc.

    Life‑sciences equipment maker reporting Q3 2026 results.

  • Executive
    Prahlad Singh

    CEO of Revvity who commented on the results.

Read at source← All news

StoryRevvity beats Q3 expectations and raises 2026 guidance

Also covered by

4 outlets

Related articles

NOV 3
$RVTYMed

Revvity, Inc. Q3 2026 Earnings Call Summary

Revvity, Inc. reported Q3 2026 earnings, highlighting a 9% organic growth in Life Sciences, driven by reagent and software demand. Management raised full-year guidance to 5% growth, citing AI-related demand and operational efficiencies. The company expects sustainable margins and plans to divest its China immunodiagnostics business in 2027. Key growth areas include reagents and Signals software, with AI-native offerings launching in 2026.

finance.yahoo.com7 min
NOV 3
$RVTYHighAI 9/10

Revvity Shares Jump Nearly 6% as Q3 Earnings Beat Forecasts and 2026 Guidance Improves

Revvity (RVTY) shares rose 5.55% premarket after Q3 2026 earnings beat estimates, with adjusted EPS of $1.37 vs. $1.30 expected. Revenue grew 4% YoY to $729M, surpassing forecasts. Pro forma revenue, excluding China Immunodiagnostics, increased 7% to $710M. Life Sciences revenue grew 10.8% to $380M, while Diagnostics saw a 2% reported decline but 4% pro forma growth.

finance.yahoo.com5 min
NOV 3
$RVTYHighAI 8/10

Revvity Q3 2026 slides: strong growth, margin expansion lift outlook

Revvity reported Q3 2026 revenue of $710M, up 7% YoY, with adjusted operating margins expanding to 29.4%. EPS grew 21% to $1.37. The company raised full-year guidance, citing strong demand and operational improvements. Life Sciences and Diagnostics segments showed growth, with the Americas and Europe outperforming Asia-Pacific. Revvity's stock surged 8.85% premarket to $165.01.

investing.com2 min
NOV 3
$RVTYHighAI 8/10

Revvity Shares Jump After Strong Q3, Raises Outlook

Revvity shares rose 8.8% premarket after Q3 2026 earnings beat expectations, with adjusted EPS at $1.37 and revenue at $729M. The company raised FY 2026 guidance, targeting $5.40–$5.45 EPS and $2.86B revenue. Life Sciences segment grew 11%, and operating margin improved to 13.1%. CEO attributed results to strong execution. TD Cowen raised its price target to $175 in October.

tradingpedia.com2 min
NOV 3
$RVTYHighAI 8/10

Revvity Announces Financial Results for the Third Quarter of 2026

REVVITY, INC. (RVTY) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE November 3, 2026 Revvity Announces Financial Results for the Third Quarter of 2026 • Revenue of $729 million; pro forma revenue of $710 million; 7% pro forma revenue growth; 7% pro forma organic revenue growth • GAAP EPS from continuing operations of $0.56 ;

SEC EDGAR 8-K2 min